54 results
8-K
EX-99.1
HGENQ
Humanigen, Inc
12 Apr 22
Regulation FD Disclosure
9:00am
treatment for COVID - 19; it is not currently approved or authorized for use in any c ountry PREACH – M Trial Phase 2/3 for CMML: Recruitment Commenced
8-K
EX-99.1
HGENQ
Humanigen, Inc
2 Dec 21
Other Events
8:00am
in any c ountry LIVE - AIR ACTIV - 5 Recruitment sites 35 55 (Including 2 in S. Korea) Overall enrollment 520 up to 550 CRP<150 mg/L 351* 400* Inclusion
8-K
EX-99.1
wocdhlh4aszv3t4
9 Nov 21
Regulation FD Disclosure
8:00am
8-K
EX-99.1
lwur4s
14 Sep 21
Regulation FD Disclosure
5:00pm
8-K
EX-10.1
7bhjhkrl8m6seesv
14 Jan 21
Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19
4:30pm
8-K
EX-99.1
leh6 hnwuox3nm
11 Jan 21
Regulation FD Disclosure
6:07am
424B3
9i1phu xguyclca9
12 Nov 20
Prospectus supplement
4:15pm
424B3
7letwapklump9jljr5s6
17 Aug 20
Prospectus supplement
8:45am
8-K
EX-99.1
u1vu2x xwpqp9
10 Aug 20
Regulation FD Disclosure
9:08am
424B3
vhljk6m7siqzt9kq8jq
5 Aug 20
Prospectus supplement
5:06pm